Takeda gets action date for alogliptin in key US market
This article was originally published in Scrip
Executive Summary
The US FDA has set a Prescription Drug User Fee Act action date of 25 January 2012 for two products containing Takeda's DPP-4 inhibitor alogliptin, moving the oral antidiabetic closer to possible approval in what will be a critical market.